Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues
| Autor: | Gisha Mohan, Amjad Basheer, Tesil Nedumkallel Sani, Sukrita Menon, Nisha Nigil Haroon, Nasvin Imamudeen, Anoop Mohamed Iqbal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Toxicology
Bioinformatics Glucagon-Like Peptide-1 Receptor law.invention 03 medical and health sciences Lixisenatide chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Glucagon-Like Peptide 1 medicine Humans Hypoglycemic Agents Pharmacology (medical) 030212 general & internal medicine Glucagon-like peptide 1 receptor Pharmacology business.industry Liraglutide Semaglutide chemistry Tolerability Diabetes Mellitus Type 2 Exenatide 030211 gastroenterology & hepatology Dulaglutide business medicine.drug |
| Zdroj: | Current drug safety. 16(2) |
| ISSN: | 2212-3911 |
| Popis: | Abstract:: Glucagon-like peptide- 1 receptor analogs (GLP-1RAs) are incretin mimetics with potent glucose-dependent insulinotropic action that translates to glycemic control in people with type- -2 diabetes mellitus (T2DM). These agents potentially have the ability to stimulate proliferation or prevent apoptosis of pancreatic β-cells, induce weight-loss and provide vascular benefits in patients with T2DM. Newer GLP-1RA, semaglutide has shown a robust reduction in HbA1c up to 1.5 - 1.8%. However, individual differences exist between the different GLP-1RAs, in terms of efficacy, pharmacokinetics, tolerability, and vascular protection. The potential of vascular protection offered by newer anti-diabetic agents has generated a lot of excitement in the field of diabetes, and to a large extent, is now driving treatment decisions. So far, six cardiovascular outcome trials of GLP-1 RAs have been published, analyzing lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6), long-acting exenatide (EXSCEL), dulaglutide (REWIND), and oral semaglutide (PIONEER 6) with a follow-up duration of 2-4 years. LEADER, REWIND and SUSTAIN-6 trials have demonstrated a reduction in rates of major adverse cardiovascular events with active GLP-1 RA treatment, but ELIXA, PIONEER 6 and EXSCEL, have been neutral. In this review, we discuss the available evidence from randomized controlled trials (RCTs) analyzing the cardiovascular effects of various GLP-1 RAs with the aim of comparing individual drugs. We have also summarized the general aspects of GLP-1RAs that can be applied in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|